Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now listed on the Medicare Benefits Schedule in Australia for selection of patients’ suitability for lutetium-177 PSMA therapy. Swipe to hear from Anne Savage, CEO of the Prostate Cancer Foundation of Australia

Telix will release its H1 2025 results on Thursday 21 August 2025. An investor webcast will be held at 9:30am AEST (7:30pm EDT, Wednesday 20 August). To register for the webcast visit:

Sarcoma Awareness Month reminds us how much work remains in tackling rare cancers like soft tissue sarcoma (STS). While localized STS can often be managed with radiotherapy, treatment becomes significantly more difficult once the disease spreads. In this video, ZOLAR

Telix is proud to support the 25th Asia-Pacific Prostate Cancer Conference, taking place from 21–23 August in Sydney, Australia. Our Phase 3 ProstACT Global study for prostate cancer therapy will be highlighted throughout the event, and we’re excited to present workshops on

Telix today provides a revenue and business update for the second quarter of 2025. Unaudited total revenue for the quarter was US$204 million, representing a 63% increase year-over-year. This was primarily driven by continued strong sales of Telix’s prostate cancer imaging

This Sarcoma Awareness Month, we’re shining a spotlight on soft tissue sarcoma (STS) - a rare and often overlooked cancer that affects people of all ages. With over 70 different subtypes, STS presents a complex diagnostic and treatment challenge, with many patients facing

Telix recently supported the National Brain Tumor Society’s Glioblastoma Awareness Day on Capitol Hill, standing alongside patients, advocates, and lawmakers to honor those affected by GBM. The courage of those who shared their experiences was a powerful call to action, with

Gute Nachrichten! . Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved in Austria. With its broad indication, Illuccix® is designed to help healthcare providers deliver efficient, reliable imaging. The approval comes as demand for PSMA-PET

🧠 July 16 is Glioblastoma (GBM) Awareness Day - a moment to honor those affected by one of the most aggressive and complex brain cancers. It’s also a time to reflect on how we can do better. Despite ongoing research, treatment options for GBM remain limited with poor patient

Gozellix® (kit for preparing gallium-68 gozetotide injection), has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services (CMS). Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616

Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, has produced and delivered its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses. As one of Europe's largest radiopharmaceutical production facilities, TMS houses nine GMP lines,

Bouna notizia!. Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in Italy. Despite the proven benefits of gallium-based PSMA-PET imaging, many of the 38,000 Italian men diagnosed with prostate cancer each year have faced long wait times,

Telix celebrates Pride. A core value of Telix is Everyone Counts. To deliver on our healthcare mission of serving everyone, our team must reflect the world we live in. We value our LGBTQI team members and the amazing contribution they make. We believe that access to healthcare is

Goed nieuws! gute Nachricht! Bonne nouvelle!. Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in Belgium. With its broad indication, Illuccix® is designed to help healthcare providers deliver efficient, reliable, gallium-based imaging to

Telix has launched a novel PET radiochemistry platform based on 18F-aluminium fluoride (AlF), named AlfluorTM, which enables flexible radiolabeling of PSMA with either AlF or gallium-68 (68Ga)345. AlfluorTM also has the potential to be used with ligands targeting neuroendocrine

Join Telix this weekend in New Orleans, Louisiana for the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting - the world’s largest dedicated nuclear medicine congress. The program includes five abstract presentations and two satellite symposia

Μεγάλα νέα!. Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in Greece. In 2024, tracer and staff shortages meant that only a small fraction of Greek men diagnosed with prostate cancer were able to receive a PSMA-PET scan. Illuccix’s

Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), is now commercially available across the United States. From today, Gozellix will be available nationally through a network of Telix’s distribution partners, Cardinal Health, Inc., PharmaLogic

Gute Nachrichten! . Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved in Germany. Despite the proven benefits of PSMA-PET imaging, men in Germany have faced long wait times due to tracer shortages and infrastructure constraints. The

Boas notίcias!. Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in Portugal, good news for thousands of men with prostate cancer. With its broad indication, Illuccix is designed to help healthcare providers deliver efficient, reliable